drugset / Trial / NCT00295620

Secondary Adjuvant Long Term Study With Arimidex

NCT00295620

Phase 3 Completed 3484 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The study assesses the effect of further 2 years vs further 5 years of adjuvant treatment with anastrozole after initial 5 years of adjuvant endocrine therapy.

Timeline

Start
2004-03-01
Primary completion
2017-06-30
Completion
2017-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg Oral

Indications